NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
On July10, 2017, Neurocrine Biosciences, Inc. (the “Company”) and Patheon UK Limited (“Patheon”) entered into an Amended and Restated Product Agreement (the “Amended and Restated Product Agreement”), which amends and restates in its entirety the Product Agreement entered into on November28, 2016 between the Company and Patheon (the “Original Product Agreement”), for Patheon’s manufacture of commercial supplies of INGREZZA® (valbenazine) capsules at Patheon’s manufacturing site.
The Amended and Restated Product Agreement contains the following changes from the Original Product Agreement: (i)the finalization of the batch sizes and the corresponding pricing for 80mg INGREZZA capsules; and (ii)a clarification of the testing requirements related to the manufacture of INGREZZA. All other terms and conditions of the Original Product Agreement, as described in the Current Report on Form 8-K filed by the Company on April25, 2017, and attached to such Current Report on Form8-K as Exhibit99.2, remain substantially the same.
The foregoing does not purport to be a complete description of the Amended and Restated Product Agreement, and is qualified in its entirety by reference to the full text of the Amended and Restated Product Agreement, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the three-month period ended September30, 2017.
About NEUROCRINE BIOSCIENCES, INC. (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Company focuses on developing NBI-640756 against Essential tremor. Its research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases. Its Corticotropin-Releasing Factor (CRF) is a hypothalamic hormone released directly into the hypophyseal portal vasculature.
